Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism
| Autor: | Ali Al Qarni, Jahangir Iqbal, Gasmelseed Ahmed, Ahmad F. Alghanem, Abbas Hawwari |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Endocrinology Diabetes and Metabolism Lipoproteins Disease Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Internal medicine Diabetes mellitus medicine Animals Humans Dyslipidemias Hypolipidemic Agents Metabolic Syndrome business.industry Lipid metabolism Metabolism medicine.disease MicroRNAs 030104 developmental biology Gene Expression Regulation lipids (amino acids peptides and proteins) Metabolic syndrome business Dyslipidemia Biomarkers |
| Zdroj: | Current diabetes reviews. 14(5) |
| ISSN: | 1875-6417 |
| Popis: | Background Metabolic syndrome is associated with increased risk for both type 2 diabetes and cardiovascular disease. Development of these pathologies is associated with the disorders of lipid and lipoprotein metabolism. Dyslipidemia leads to the overproduction of potentially atherogenic lipid and lipoproteins. Furthermore, there is a decrease in the levels of high-density lipoproteins and an increase in the levels of remnant and small dense LDL particles. Conclusion In the current review, we have discussed the pathophysiology of lipoprotein biosynthesis and metabolism in the metabolic syndrome. Finally, we describe regulation of lipoprotein metabolism which may be used as a potential target for treating dyslipidemia in metabolic syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|